BeOne Medicines (BEIGF) EPS (Basic) (2015 - 2026)

BeOne Medicines (BEIGF) has reported EPS (Basic) for 12 consecutive years, with $2.12 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) rose 143.95% year-over-year to $2.12 in Q2 2026; TTM through Jun 2026 was $5.88, a 458.35% increase from a year earlier, with the FY2025 full-year figure at $2.63, up 142.96% from the prior year.
• EPS (Basic) was $2.12 for Q2 2026 at BeOne Medicines, up from $2.05 in the prior quarter.
• Over five years, EPS (Basic) peaked at $2.12 in Q2 2026 and troughed at -$5.5 in Q2 2022.
• A 5-year average of -$1.51 and a median of -$1.3 in 2024 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) plunged 684.18% in 2022 and jumped 17151.81% in 2026, its largest moves.
• Over 5 years, EPS (Basic) stood at -$4.32 in 2022, then rose by 18.46% to -$3.52 in 2023, then soared by 59.03% to -$1.44 in 2024, then surged by 142.27% to $0.61 in 2025, then jumped by 248.36% to $2.12 in 2026.
• The last three EPS (Basic) figures came in at $2.12 (Q2 2026), $2.05 (Q1 2026), and $0.61 (Q4 2025), per Business Quant data.